Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

[Is a routine second transurethral resection of the bladder still necessary after hexaminolévulinate photodynamic diagnosis-assisted TURBT?]

Doisy L, Walz J, Fakhfakh S, Rybikowski S, Koskas Y, Gravis G, Pignot G.

Prog Urol. 2019 May - Jun;29(6):332-339. doi: 10.1016/j.purol.2019.04.001. Epub 2019 May 16. French.

PMID:
31104952
2.

Extent of positive surgical margins following radical prostatectomy: impact on biochemical recurrence with long-term follow-up.

Koskas Y, Lannes F, Branger N, Giusiano S, Guibert N, Pignot G, Walz J, Rossi D, Bastide C.

BMC Urol. 2019 May 15;19(1):37. doi: 10.1186/s12894-019-0470-8.

3.

Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.

Borcoman E, De La Rochere P, Richer W, Vacher S, Chemlali W, Krucker C, Sirab N, Radvanyi F, Allory Y, Pignot G, Barry de Longchamps N, Damotte D, Meseure D, Sedlik C, Bieche I, Piaggio E.

Oncoimmunology. 2019 Mar 16;8(5):e1581556. doi: 10.1080/2162402X.2019.1581556. eCollection 2019.

4.

High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of GPR126 in Bladder Cancer.

Garinet S, Pignot G, Vacher S, Le Goux C, Schnitzler A, Chemlali W, Sirab N, Barry Delongchamps N, Zerbib M, Sibony M, Allory Y, Damotte D, Bieche I.

Mol Cancer Res. 2019 Feb;17(2):469-475. doi: 10.1158/1541-7786.MCR-18-0363. Epub 2018 Nov 6.

PMID:
30401719
5.

[French ccAFU guidelines - Update 2018-2020: Bladder cancer].

Rouprêt M, Neuzillet Y, Pignot G, Compérat E, Audenet F, Houédé N, Larré S, Masson-Lecomte A, Colin P, Brunelle S, Xylinas E, Roumiguié M, Méjean A.

Prog Urol. 2018 Nov;28(12S):S46-S78. doi: 10.1016/j.purol.2018.07.283. Epub 2018 Oct 23. Review. French.

PMID:
30366708
6.

[French ccAFU guidelines - Update 2018-2020: Upper tract urothelial carcinoma].

Rouprêt M, Xylinas E, Colin P, Houédé N, Compérat E, Audenet F, Larré S, Masson-Lecomte A, Pignot G, Brunelle S, Roumiguié M, Neuzillet Y, Méjean A.

Prog Urol. 2018 Nov;28(12S):S32-S45. doi: 10.1016/j.purol.2018.07.284. Epub 2018 Oct 11. Review. French.

PMID:
30318333
7.

[The REVELA13 observatory to study new cases of bladder tumor among women living in Bouches-du-Rhône county].

Martin T, Mantey K, Boissier R, Albert P, Grisoni V, Lechevallier E, Barriol D, Gravis G, Pignot G, Rossi D, Lorca J, Rattier C, Eghazarian C, Daou N, Davin JL, Clément C, Akiki A, Pascal L, Karsenty G.

Prog Urol. 2018 Dec;28(16):935-941. doi: 10.1016/j.purol.2018.09.004. Epub 2018 Oct 10. French.

PMID:
30316672
8.

Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen.

Gravis G, Billon E, Baldini C, Massard C, Hilgers W, Delva R, Walz J, Pignot G, Rybikowski S, Dermeche S, Thomassin J, Brunelle S, Lavaud P, Loriot Y; French Genito-Urinary Tumor Group (GETUG).

Eur J Cancer. 2018 Nov;104:236-238. doi: 10.1016/j.ejca.2018.09.002. Epub 2018 Oct 11. No abstract available.

PMID:
30316610
9.

Management of non-metastatic castrate-resistant prostate cancer: A systematic review.

Loriot Y, Supiot S, Beauval JB, Schlürmann F, Pasticier G, Sargos P, Barthélémy P, Pignot G, Maillet D, Vincendeau S, Gross E, Ploussard G, Timsit MO, Borchiellini D.

Cancer Treat Rev. 2018 Nov;70:223-231. doi: 10.1016/j.ctrv.2018.09.006. Epub 2018 Sep 21. Review.

PMID:
30300771
10.

[ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology].

Pignot G, Houédé N, Roumiguié M, Audenet F, Brunelle S, Colin P, Compérat E, Larré S, Masson-Lecomte A, Neuzillet Y, Xylinas E, Méjean A, Rouprêt M; les membres du CCAFU Vessie.

Prog Urol. 2018 Oct;28(12):567-574. doi: 10.1016/j.purol.2018.07.003. Epub 2018 Sep 8. Review. French.

PMID:
30205925
11.

Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.

Rouanne M, Roumiguié M, Houédé N, Masson-Lecomte A, Colin P, Pignot G, Larré S, Xylinas E, Rouprêt M, Neuzillet Y.

World J Urol. 2018 Nov;36(11):1727-1740. doi: 10.1007/s00345-018-2332-5. Epub 2018 Jun 1. Review.

PMID:
29855698
12.

Systemic treatments for high-risk localized prostate cancer.

Pignot G, Maillet D, Gross E, Barthelemy P, Beauval JB, Constans-Schlurmann F, Loriot Y, Ploussard G, Sargos P, Timsit MO, Vincendeau S, Pasticier G, Borchiellini D.

Nat Rev Urol. 2018 Aug;15(8):498-510. doi: 10.1038/s41585-018-0017-x. Review.

PMID:
29765147
13.

Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUG.

Beauval JB, Loriot Y, Hennequin C, Rozet F, Barthelemy P, Borchiellini D, Schlürmann Constans F, Gross E, Maillet D, Pasticier G, Pignot G, Timsit MO, Vincendeau S, Ploussard G, Sargos P.

Crit Rev Oncol Hematol. 2018 Feb;122:144-149. doi: 10.1016/j.critrevonc.2017.12.012. Epub 2017 Dec 30. Review.

PMID:
29458782
14.

mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer.

Le Goux C, Vacher S, Pignot G, Sibony M, Barry Delongchamps N, Terris B, Piaggio E, Zerbib M, Damotte D, Bieche I.

Oncoimmunology. 2017 Aug 14;6(11):e1358330. doi: 10.1080/2162402X.2017.1358330. eCollection 2017.

15.

[Surgical approach and sexual outcomes after radical prostatectomy].

Caillet K, Lipsker A, Alezra E, De Sousa P, Pignot G.

Prog Urol. 2017 Apr;27(5):283-296. doi: 10.1016/j.purol.2017.03.001. Epub 2017 Apr 6. Review. French.

PMID:
28392432
16.

Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.

Le Goux C, Damotte D, Vacher S, Sibony M, Delongchamps NB, Schnitzler A, Terris B, Zerbib M, Bieche I, Pignot G.

Urol Oncol. 2017 May;35(5):257-263. doi: 10.1016/j.urolonc.2017.01.014. Epub 2017 Mar 11.

PMID:
28291636
17.

Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.

Dusaud M, Malavaud B, Bayoud Y, Sebe P, Hoepffner JL, Salomon L, Houlgatte A, Pignot G, Rigaud J, Fléchon A, Pfister C, Rouprêt M, Soulié M, Méjean A, Durand X.

J Surg Oncol. 2016 Dec;114(8):992-996. doi: 10.1002/jso.24464. Epub 2016 Nov 18.

PMID:
27859263
18.

[CCAFU french national guidelines 2016-2018 on bladder cancer].

Rouprêt M, Neuzillet Y, Masson-Lecomte A, Colin P, Compérat E, Dubosq F, Houédé N, Larré S, Pignot G, Puech P, Roumiguié M, Xylinas E, Méjean A.

Prog Urol. 2016 Nov;27 Suppl 1:S67-S91. doi: 10.1016/S1166-7087(16)30704-7. Review. French.

PMID:
27846935
19.

[CCAFU french national guidelines 2016-2018 on upper tract tumors].

Rouprêt M, Colin P, Xylinas E, Compérat E, Dubosq F, Houédé N, Larré S, Masson-Lecomte A, Neuzillet Y, Pignot G, Puech P, Roumiguié M, Méjean A.

Prog Urol. 2016 Nov;27 Suppl 1:S55-S66. doi: 10.1016/S1166-7087(16)30703-5. Review. French.

PMID:
27846934
20.

Is negative multiparametric magnetic resonance imaging really able to exclude significant prostate cancer? The real-life experience.

Branger N, Maubon T, Traumann M, Thomassin-Piana J, Brandone N, Taix S, Touzlian J, Brunelle S, Pignot G, Salem N, Gravis G, Walz J.

BJU Int. 2017 Mar;119(3):449-455. doi: 10.1111/bju.13657. Epub 2016 Oct 4.

21.

Encrusted Uretero-pyelitis: Case Report.

Saljoghi R, Lipsker A, Caillet K, Malaterre J, Le Roux F, Pignot G, Saint F.

Urol Case Rep. 2016 May 21;7:58-60. doi: 10.1016/j.eucr.2016.04.014. eCollection 2016 Jul.

22.

Safety and Feasibility of Laparoscopic Nephrectomy for Big Tumors (≥ 10 cm): A Retrospective Multicentric Study.

Verhoest G, Couapel JP, Oger E, Rioux-Leclercq N, Pignot G, Patard JJ, Bex A, Panayotopoulos P, Bigot P, Eret V, Hora M, Turna B, Lefevre M, Rigaud J, Tillou X, Doerfler A, Xylinas E, Soorojebally Y, Rouprêt M, Lagabrielle S, Bernhard JC, Long JA, Berger J, Ravier E, Paparel P, Salomon L, Rodriguez AR, Bensalah K.

Clin Genitourin Cancer. 2016 Aug;14(4):e335-40. doi: 10.1016/j.clgc.2016.01.007. Epub 2016 Jan 27.

23.

[Neoadjuvant targeted therapies in renal cell carcinoma].

Bigot P, Pignot G, Bernhard JC, Patard JJ.

Prog Urol. 2016 Mar;26(3):191-6. doi: 10.1016/j.purol.2015.12.003. Epub 2016 Jan 15. Review. French.

PMID:
26781767
24.

[Observational survey of the French Urological Association Oncology Committee (CCAFU) evaluating the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment].

Neuzillet Y, Colin P, Comperat E, Dubosq F, Houede N, Larre S, Masson-Lecomte A, Pignot G, Puech P, Roumiguie M, Xylinas E, Mejean A, Roupret M.

Prog Urol. 2016 Mar;26(3):181-90. doi: 10.1016/j.purol.2015.12.002. Epub 2016 Jan 8. French.

PMID:
26777686
25.

[Molecular, preclinical, and clinical comparative data regarding different strains of bacillus Calmette-Guérin (BCG): Review by the French Urological Association Oncology Committee (CCAFU)].

Neuzillet Y, Dubosq F, Xylinas E, Colin P, Comperat E, Houede N, Larre S, Masson-Lecomte A, Pignot G, Puech P, Roumiguie M, Mejean A, Roupret M.

Prog Urol. 2016 Feb;26(2):121-8. doi: 10.1016/j.purol.2015.10.011. Epub 2015 Nov 27. Review. French.

PMID:
26638801
26.

[Recent advances in bladder urothelial carcinogenesis].

Pignot G, le Goux C, Bieche I.

Bull Cancer. 2015 Dec;102(12):1020-35. doi: 10.1016/j.bulcan.2015.10.004. Epub 2015 Nov 23. Review. French.

27.

Implication de la voie PD1/PDL1 et de la voie CTLA4/CD80 dans les tumeurs urothéliales.

Pignot G, Le Goux C, Bieche I, Vacher S, Barry de Longchamps N, Sibony M, Zerbib M.

Prog Urol. 2015 Nov;25(13):762. doi: 10.1016/j.purol.2015.08.096. French. No abstract available.

PMID:
26544291
28.

Faut-il proposer une seconde résection systématique pour toutes les tumeurs de vessie n'infiltrant pas le muscle vésical à risque élevé ?

Lipsker A, Hammoudi Y, Bessede T, Patard J, Pignot G.

Prog Urol. 2015 Nov;25(13):761. doi: 10.1016/j.purol.2015.08.093. French. No abstract available.

PMID:
26544287
29.

Pratique quotidienne et suivi des recommandations pour la prise en charge des tumeurs de vessie n'infiltrant pas le muscle : résultats d'une enquête du CCAFU auprès des urologues français.

Mason-Lecomte A, Xylinas E, Colin P, Comperat E, Dubosq F, Houedee N, Larré S, Neuzillet Y, Pignot G, Puech P, Mejean A, Qvick B, Bes P, Rouprêt M.

Prog Urol. 2015 Nov;25(13):758. doi: 10.1016/j.purol.2015.08.087. French. No abstract available.

PMID:
26544282
30.

Facteurs de récidive après curage rétro-péritonéal pour tumeur germinale : étude rétrospective multicentrique.

Murez T, Durand X, Rivoire M, Fournier G, Dariane C, Rouprêt M, Lugagne J, Bosset P, Pignot G, Hetet J, Rigaud J, Safsaf R, Pfister C, Daste A, Sèbe P, Malavaud B, Bossavy J, Houlgatte A, Avances C, Camparo P, Flechon A, Culine S, Iborra F, Mottet N, Coloby P, Soulié M.

Prog Urol. 2014 Nov;24(13):865. doi: 10.1016/j.purol.2014.08.180. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461706
31.

Facteurs prédictifs de procédures chirurgicales complémentaires lors des résections de masses résiduelles rétro-péritonéales des tumeurs germinales post-chimiothérapie. Exploitation de la base française collaborative CCAFU-OGE.

Bayoud Y, Fournier G, Rouprêt M, Lugagne P, Dusaud M, Pignot G, Rigaud J, Rivoire M, Safsaf A, Sébe P, Malavaud B, Houlgatte A, Durand X.

Prog Urol. 2014 Nov;24(13):864. doi: 10.1016/j.purol.2014.08.178. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461705
32.

Étude multicentrique de l'histologie des masses résiduelles des tumeurs germinales après chimiothérapie : existe-t-il des facteurs prédictifs ?

Dusaud M, Rivoire M, Bayoud Y, Sèbe P, Malavaud B, Daste A, Dariane C, Pignot G, Thoulouzan M, Bosset P, Safsaf A, Rigaud J, Houlgatte A, Durand X.

Prog Urol. 2014 Nov;24(13):864. doi: 10.1016/j.purol.2014.08.179. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461704
33.

Le cancer de vessie chez le sujet jeune, une étude de population française.

Compérat E, Larré S, Neuzillet Y, Vordos D, Soulié M, Azzouzi A, Pignot G, Durand X, Quintens H, Houede N, Jeglischi S, El Bakri A, Bigot P, Lebdai S, Rouprêt M, Pfister C.

Prog Urol. 2014 Nov;24(13):846. doi: 10.1016/j.purol.2014.08.140. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461667
34.

L'Ischémie n'est pas un facteur d'insuffisance rénale chronique après néphrectomie partielle sur rein unique.

Pignot G, Bahi R, Bensalah K, Oger E, Laguna P, Barwari K, Rigaud J, Rouprêt M, Bernhard J, Long J, Zisman A, Berger J, Paparel P, Lechevallier E, Bertini R, Salomon L, Bex A, Farfara R, Ljungberg B, Rodriguez A, Patard J.

Prog Urol. 2014 Nov;24(13):822. doi: 10.1016/j.purol.2014.08.087. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461614
35.

[Follow-up of urothelial carcinoma: Review of the Cancer Committee of the French Association of Urology].

Colin P, Neuzillet Y, Pignot G, Rouprêt M, Comperat E, Larré S, Roy C, Quintens H, Houedé N, Soulié M, Pfister C; membres du Comité de cancérologie de l’Association française d’urologie.

Prog Urol. 2015 Sep;25(10):616-24. doi: 10.1016/j.purol.2015.05.012. Epub 2015 Jun 30. Review. French.

PMID:
26141291
36.

[Role of blue-light cystoscopy in the management of non-muscle invasive bladder cancer].

Pignot G.

Prog Urol. 2015 Sep;25(10):607-15. doi: 10.1016/j.purol.2015.05.003. Epub 2015 Jun 15. Review. French.

PMID:
26088583
37.

Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.

Mathieu R, Pignot G, Ingles A, Crepel M, Bigot P, Bernhard JC, Joly F, Guy L, Ravaud A, Azzouzi AR, Gravis G, Chevreau C, Zini L, Lang H, Pfister C, Lechevallier E, Fais PO, Berger J, Vayleux B, Roupret M, Audenet F, Descazeaud A, Rigaud J, Machiels JP, Staehler M, Salomon L, Ferriere JM, Kleinclauss F, Bensalah K, Patard JJ.

Urol Oncol. 2015 Aug;33(8):339.e9-15. doi: 10.1016/j.urolonc.2015.05.014. Epub 2015 Jun 16.

PMID:
26087971
38.

Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old.

Compérat E, Larré S, Roupret M, Neuzillet Y, Pignot G, Quintens H, Houéde N, Roy C, Durand X, Varinot J, Vordos D, Rouanne M, Bakhri MA, Bertrand P, Jeglinschi SC, Cussenot O, Soulié M, Pfister C.

Virchows Arch. 2015 May;466(5):589-94. doi: 10.1007/s00428-015-1739-2. Epub 2015 Feb 20.

PMID:
25697540
39.

[Renal angiomyolipoma with inferior vena cava thrombosis during pregnancy].

Bidault V, Pignot G, Rocher L, Glas L, Patard JJ.

Prog Urol. 2015 Apr;25(5):288-92. doi: 10.1016/j.purol.2015.01.002. Epub 2015 Jan 28. French.

PMID:
25638747
40.

T-helper 1 immunoreaction influences survival in muscle-invasive bladder cancer: proof of concept.

Ingels A, Sanchez Salas RE, Ravery V, Fromont-Hankard G, Validire P, Patard JJ, Pignot G, Prapotnich D, Olivier F, Galiano M, Barret E, Rozet F, Weber N, Cathelineau X.

Ecancermedicalscience. 2014 Dec 1;8:486. doi: 10.3332/ecancer.2014.486. eCollection 2014.

41.

[Ischemia is not an independent predictive factor of chronic renal failure after partial nephrectomy in a solitary kidney in patients without pre-operative renal insufficiency].

Bahi R, Pignot G, Hammoudi Y, Bensalah K, Oger E, Laguna P, Barwari K, Bessède T, Rigaud J, Roupret M, Bernhard JC, Long JA, Zisman A, Berger J, Paparel P, Lechevallier E, Bertini R, Salomon L, Bex A, Farfara R, Ljungberg B, Rodriguez AR, Patard JJ.

Prog Urol. 2015 Jan;25(1):27-33. doi: 10.1016/j.purol.2014.09.039. Epub 2014 Oct 23. French.

PMID:
25450751
42.

Are urologists and radiologists equally effective in determining the RENAL Nephrometry score?

Benadiba S, Verin AL, Pignot G, Bessede T, Drai J, Bahi R, Toussile W, Rocher L, Patard JJ.

Ann Surg Oncol. 2015 May;22(5):1618-24. doi: 10.1245/s10434-014-4152-1. Epub 2014 Nov 11.

PMID:
25384701
43.

The accuracy of renal tumor biopsy: analysis from a national prospective study.

Bernhard JC, Bigot P, Pignot G, Baumert H, Zini L, Lang H, Crepel M, Monod P, Salomon L, Bellec L, Roupret M, Schneider M, Xylinas E, Paparel P, Bruyere F, Berger J, Ansieau JP, Gimel P, Salome F, Castagnola C, Pfister C, Legraverend JM, Timsit MO, Le Pellec L, Auberget JL, Rolland E, Mallet R, Mejean A, Patard JJ; NEPHRON Study Group.

World J Urol. 2015 Aug;33(8):1205-11. doi: 10.1007/s00345-014-1432-0. Epub 2014 Nov 6.

PMID:
25373933
44.

[Should we propose a systematic second transurethral resection of the bladder for all high-risk non-muscle invasive bladder cancers?].

Lipsker A, Hammoudi Y, Parier B, Drai J, Bahi R, Bessede T, Patard JJ, Pignot G.

Prog Urol. 2014 Sep;24(10):640-5. doi: 10.1016/j.purol.2014.03.006. Epub 2014 Apr 29. French.

PMID:
25214293
45.

[Conservative management of urothelial carcinomas of the upper tract: systematic review for the yearly scientific report of the French National Association of Urology].

Pignot G, Colin P, Rouprêt M, Traxer O.

Prog Urol. 2014 Nov;24(15):1011-20. doi: 10.1016/j.purol.2014.07.007. Epub 2014 Sep 7. Review. French.

PMID:
25205341
46.

Nephron-sparing surgery is superior to radical nephrectomy in preserving renal function benefit even when expanding indications beyond the traditional 4-cm cutoff.

Pignot G, Bigot P, Bernhard JC, Bouliere F, Bessede T, Bensalah K, Salomon L, Mottet N, Bellec L, Soulié M, Ferrière JM, Pfister C, Drai J, Colombel M, Villers A, Rigaud J, Bouchot O, Montorsi F, Bertini R, Belldegrun AS, Pantuck AJ, Patard JJ.

Urol Oncol. 2014 Oct;32(7):1024-30. doi: 10.1016/j.urolonc.2014.03.012. Epub 2014 Jul 2.

PMID:
24996775
47.

[Pronostic value of parenchyma renal invasion of pT3 upper tract urinary carcinoma].

Bruzzi M, Le Goux C, Pignot G, Amsellem-Ouazana D, Vieillefond A, Patard JJ, Zerbib M.

Prog Urol. 2014 Jul;24(9):556-62. doi: 10.1016/j.purol.2013.12.005. Epub 2014 Jan 21. French.

PMID:
24975790
48.

Prostate cancer incidence on cystoprostatectomy specimens is directly linked to age: results from a multicentre study.

Pignot G, Salomon L, Lebacle C, Neuzillet Y, Lunardi P, Rischmann P, Zerbib M, Champy C, Roupret M, Peyronnet B, Verhoest G, Murez T, Quintens H, Larré S, Houédé N, Compérat E, Soulié M, Pfister C.

BJU Int. 2015 Jan;115(1):87-93. doi: 10.1111/bju.12803. Epub 2014 Aug 11.

49.

Influence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carcinoma after radical nephroureterectomy.

Hurel S, Rouprêt M, Seisen T, Comperat E, Phé V, Droupy S, Audenet F, Pignot G, Cathelineau X, Guy L, Cussenot O, Ouzzane A, Bozzini G, Nison L, Ruffion A, Colin P.

World J Urol. 2015 Mar;33(3):335-41. doi: 10.1007/s00345-014-1311-8. Epub 2014 May 9.

PMID:
24810657
50.

Surgical management of locally advanced and metastatic renal cancer: neoadjuvant and adjuvant strategies.

Pignot G, Drai J, Patard JJ.

Minerva Urol Nefrol. 2014 Mar;66(1):49-55. Review.

PMID:
24721940

Supplemental Content

Loading ...
Support Center